Skip to main content

LeMaitre Vascular Inc Value Stock - Dividend - Research Selection

Lemaitre vascular inc

ISIN: US5255582018 , WKN: A0LB2B

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Dividend Champion, Contender, And Challenger Highlights: Week Of August 31

2025-08-30
See here for weekly updates on Dividend Champions, Contenders, and Challengers. Stay informed on dividend changes, ex-dividend and pay dates.

LeMaitre to Participate at Upcoming Investor Conferences in September

2025-08-28
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences. 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 Encore Boston Harbor, Everett, MA Dorian LeBlanc, CFO, will present at 1:30 PM ET Cantor Global Healthcare Conference Thursday, September 4, 2025 InterContinental New York Barclay Hotel, New York, NY Dorian LeBlanc, CFO, will present at 10:55 AM ET Morg

Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think "Yes"

2025-08-27
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

Trump Wins... So Far - July Dividend Income Report

2025-08-21
Telus spun off its wireless tower infrastructure operations and created Terrion, now Canada’s largest dedicated wireless tower operator. Click to read.

Dividend Champion, Contender, And Challenger Highlights: Week Of August 17

2025-08-15
Read our weekly summary of companies that changed their dividends, companies with upcoming ex-dividend dates, and companies with upcoming pay dates. Access the full article here.

Should LeMaitre Vascular’s (LMAT) Earnings Jump and Dividend Hike Prompt a Closer Look from Investors?

2025-08-15
LeMaitre Vascular, Inc. recently reported second-quarter earnings, with sales reaching US$64.23 million and net income rising to US$13.78 million, both up from the prior year, and declared a quarterly dividend of US$0.20 per share payable in September 2025. The company’s ability to fund growth initiatives from strong internal cash flow, without needing external financing, underscores operational stability and supports expansion plans. We’ll assess how LeMaitre’s robust earnings growth and...

5 Revealing Analyst Questions From LeMaitre’s Q2 Earnings Call

2025-08-13
LeMaitre’s second quarter saw a strong market reaction, reflecting outperformance across key segments and positive investor sentiment. Management attributed the results to robust sales growth in catheters and grafts, with notable contributions from international markets such as EMEA and Asia-Pacific. CEO George LeMaitre cited the successful European launch of Artegraft and increased adoption of RestoreFlow, particularly in cardiac applications, as primary growth drivers. The quarter also benefit

LMAT Q2 Deep Dive: International Expansion and Product Momentum Drive Upbeat Outlook

2025-08-13
Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 15% year on year to $64.23 million. Guidance for next quarter’s revenue was optimistic at $62.2 million at the midpoint, 2.1% above analysts’ estimates. Its GAAP profit of $0.60 per share was 5.8% above analysts’ consensus estimates.

LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why

2025-08-11
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

LeMaitre Vascular Second Quarter 2025 Earnings: Beats Expectations

2025-08-09
LeMaitre Vascular ( NASDAQ:LMAT ) Second Quarter 2025 Results Key Financial Results Revenue: US$64.2m (up 15% from 2Q...